Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Apr;128(8):1415-1417.
doi: 10.1038/s41416-023-02181-6. Epub 2023 Feb 6.

Immune checkpoint inhibitor combinations-current and emerging strategies

Robert J Walsh  1 , Raghav Sundar  1   2   3   4   5 , Joline S J Lim  6   7   8
Affiliations
Editorial

Immune checkpoint inhibitor combinations-current and emerging strategies

Robert J Walsh et al. Br J Cancer. 2023 Apr.

Abstract

In an attempt to overcome resistance to immune checkpoint inhibitors (ICI), an ever-increasing number of trials are exploring combination treatment approaches. Outcomes of a novel ICI doublet presented by Desai and colleagues are discussed along with emerging novel strategies and a view to future ongoing rational trial design maximising patient benefit.

PubMed Disclaimer

Conflict of interest statement

RW reported serving on the advisory board of Pfizer; receiving honoraria from Pfizer outside the submitted work. RS reported serving on the advisory board of Bristol Myers Squibb, Merck, Eisai, Bayer, Taiho, Novartis, MSD, DKSH, and GSK; receiving honoraria from MSD, Eli Lilly, Bristol Myers Squibb, Roche, Taiho, AstraZeneca, Ipsen, and DKSH; and receiving grants from Roche, AstraZeneca, Taiho, Eisai, DKSH, Paxman Coolers, Natera, and MSD outside the submitted work. JL reported advisory activity with AstraZeneca, Novartis, Roche, DKSH, Pfizer and MSD; receiving honoraria from AstraZeneca, Novartis, Roche, DKSH, MSD, Eisai, Pierre Fabre; receiving research funding from CTI biopharma, Daiichi Sankyo, Synthon pharmaceuticals; and receiving a travel grant from AstraZeneca and MSD outside the submitted work.

Figures

Fig. 1
Fig. 1. Currently approved (left) and emerging (right) strategies in immune checkpoint inhibitor (ICI) combination therapy.
ADC antibody–drug conjugate, BTLA B- and T-lymphocyte attenuator, CAR-T chimeric antigen receptor T cell, CDK4/6 cyclin-dependent kinase 4 and 6, CTLA-4 cytotoxic T-lymphocyte-associated antigen 4, DC dendritic cell, DDR DNA damage repair, FMT faecal microbiota transplant, HDAC histone deacetylase, IFN-γ interferon-γ, IL-2 interleukin-2, LAG-3 lymphocyte-activation gene 3, MAb monoclonal antibody, PD-1 programmed death 1, PD-L1 programmed death ligand 1, PI3K phosphatidylinositol 3-kinase, TIGIT T-cell immunoreceptor tyrosine-based inhibition motif domain, TIM-3 T-cell immunoglobulin mucin domain-3 protein, VEGF vascular endothelial growth factor, VISTA V-domain immunoglobulin-containing suppressor of T-cell activation.
See this image and copyright information in PMC

References

    1. Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of immunotherapy combination strategies in cancer. Cancer Discov. 2021;11:1368–97. doi: 10.1158/2159-8290.CD-20-1209. - DOI - PMC - PubMed
    1. Wang Y, Zhang H, Liu C, Wang Z, Wu W, Zhang N, et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. J Hematol Oncol. 2022;15:111. doi: 10.1186/s13045-022-01325-0. - DOI - PMC - PubMed
    1. Johnson ML, Fox W, Lee Y-G, Lee KH, Ahn HK, Kim Y-C, et al. ARC-7: randomized phase 2 study of domvanalimab + zimberelimab ± etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC) J Clin Oncol. 2022;40:397600. doi: 10.1200/JCO.2022.40.36_suppl.397600. - DOI
    1. Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up. Ann Oncol. 2019;30:970–6. doi: 10.1093/annonc/mdz127. - DOI - PMC - PubMed
    1. Voss MH, Azad AA, Hansen AR, Gray JE, Welsh SJ, Song X, et al. A randomized phase II study of MEDI0680 in combination with durvalumab versus nivolumab monotherapy in patients with advanced or metastatic clear-cell renal cell carcinoma. Clin Cancer Res. 2022;28:3032–41. doi: 10.1158/1078-0432.CCR-21-4115. - DOI - PMC - PubMed

Publication types

Substances